OPKO Health (NASDAQ:OPK) Lowered to Sell Rating by StockNews.com

OPKO Health (NASDAQ:OPK) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.

A number of other analysts have also weighed in on OPK. HC Wainwright restated a “buy” rating and set a $3.00 target price on shares of OPKO Health in a report on Wednesday, January 8th. Piper Sandler reissued an “overweight” rating and issued a $3.00 price objective on shares of OPKO Health in a research report on Tuesday, September 17th. Finally, Barrington Research reissued an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research report on Friday, November 8th.

OPKO Health Stock Performance

OPK opened at $1.47 on Wednesday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The stock has a market cap of $1.00 billion, a price-to-earnings ratio of -7.74 and a beta of 1.63. The stock’s 50 day moving average price is $1.55 and its 200-day moving average price is $1.50. OPKO Health has a one year low of $0.86 and a one year high of $1.76.

Insider Buying and Selling

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 500,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was purchased at an average price of $1.48 per share, for a total transaction of $740,000.00. Following the purchase, the chief executive officer now directly owns 213,036,477 shares in the company, valued at approximately $315,293,985.96. This trade represents a 0.24 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders bought 1,804,255 shares of company stock worth $2,764,605 in the last 90 days. Insiders own 47.26% of the company’s stock.

Institutional Investors Weigh In On OPKO Health

Several institutional investors have recently bought and sold shares of OPK. FMR LLC boosted its holdings in shares of OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares during the last quarter. Algert Global LLC purchased a new stake in shares of OPKO Health during the second quarter worth $44,000. Orion Portfolio Solutions LLC purchased a new stake in shares of OPKO Health during the third quarter worth $45,000. Private Advisor Group LLC increased its position in shares of OPKO Health by 242.7% during the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 25,000 shares during the period. Finally, World Investment Advisors LLC acquired a new position in shares of OPKO Health during the third quarter worth $61,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.